New strategies for treating AIDS.
To date, the effective management of HIV-1 infection by anti-retroviral drugs has proved remarkably difficult to achieve. This is primarily due to the ease with which HIV-1 becomes resistant to drugs which initially may be very effective at blocking viral replication. In a recent issue of Science, two promising new AIDS treatments were reported. The first described the use of retroviral-type zinc finger structures found in the HIV-1 nucleocapsid protein as targets for antiretroviral drugs. THe second demonstrated the feasibility of the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl) adenine as a postexposure prophylaxis in blocking HIV-1 infection.
Sandstrom
P A
PA
Retrovirus Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Folks
T M
TM
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002213:Capsid; D015195:Drug Design; D004352:Drug Resistance, Microbial; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000068698:Tenofovir; D014758:Viral Core Proteins; D014779:Virus Replication / Q000187:drug effects; D016335:Zinc Fingers
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D014758:Viral Core Proteins; D000068698:Tenofovir; D000225:Adenine